Revolving Door Policy

Corruption

 

Government corruption, kickbacks, lobbyists, unethical policies in government. Legislation without regulation. The revolving door of deceitful individuals from unscrupulous corporations to government entities has created a cesspool of hazardous regulations, and unethical profits. 

 

What is the Revolving Door? 

 

In politics, the "revolving door" is a movement of personnel between roles as legislators and regulators in the industries affected by the legislation and regulation.

 

In some cases, the roles are performed in sequence but in certain circumstances may be performed at the same time. Political analysts claim that an unhealthy relationship can develop between the private sector and government, based on the granting of reciprocated privileges to the detriment of the nation and can lead to regulatory capture.

 

Governments hire industry professionals for their private sector experience, their influence within corporations that the government is attempting to regulate or do business with, and in order to gain political support (donations and endorsements) from private firms.

 

Government Hires Industry Professionals

 

Industry, in turn, hires people out of government positions to gain personal access to government officials, seek favorable legislation/regulation and government contracts in exchange for high-paying employment offers, and get inside information on what is going on in government.

 

The lobbying industry is especially affected by the revolving door concept, as the main asset for a lobbyist is contacts with and influence on government officials. This industrial climate is attractive for ex-government officials. It can also mean substantial monetary rewards for the lobbying firms and government projects and contracts in the hundreds of millions for those they represent. -Wikipedia

This is a list of men and women whom we have

put our trust in for our safety.

 

 

David W. Beier.

Former head of government affairs for Genentech, Inc.

Chief domestic policy advisor to Al Gore when he was Vice President.

 

Linda J. Fisher.

Former Assistant administrator of the United States Environmental Protection Agency’s Office of Pollution Prevention, Pesticides, and Toxic Substances.

 

Was Vice President of Government and Public Affairs for Monsanto Corporation.  Now a Vice President Safety, Health and Environment and Chief Sustainability Officer of DuPont.

Michael A. Friedman, M.D.

Former acting commissioner of the United States Food and Drug Administration (FDA) Department of Health and Human Services.

 

Now senior vice-president for clinical affairs at G. D. Searle & Co., a pharmaceutical division of Monsanto Corporation.

 

L. Val Giddings.

Former biotechnology regulator and (bio-safety) negotiator at the United States Department of Agriculture (USDA/APHIS).

 

Now Vice President for Food & Agriculture of the Biotechnology Industry Organization (BIO). Largest trade organization to serve and represent the biotechnology industry in the United States and around the world.

 

Marcia Hale.

Former assistant to the President of the United States and director for intergovernmental affairs.

 

Now Director of International Government Affairs for Monsanto Corporation.

Michael (Mickey) Kantor.

Former Secretary of the United States Department of Commerce and former Trade Representative of the United States.

Now member of the board of directors of Monsanto Corporation.

 

Terry Medley.

Former administrator of the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture, former chair and vice-chair of the United States Department of Agriculture Biotechnology Council, former member of the U.S. Food and Drug Administration (FDA) food advisory committee.

 

Now Director of Regulatory and External Affairs of Dupont Corporation’s Agricultural Enterprise.

 

Margaret Miller.

Former chemical laboratory supervisor for Monsanto.

Now Deputy Director of Human Food Safety and Consultative Services, New Animal Drug Evaluation Office, Center for Veterinary Medicine in the United States Food and Drug Administration (FDA).

 

Michael Phillips.

Recently with the National Academy of Science Board on Agriculture.

Now head of regulatory affairs for the Biotechnology Industry Organization.

 

William D. Ruckelshaus.

Former chief administrator of the United States Environmental Protection Agency (USEPA), … now (and for the past 12 years) a member of the board of directors of Monsanto Corporation.

 

Michael Taylor.

January 2010, Deputy Commissioner for the FDA

He is the first individual to hold the position, which was created along with a new Office of Foods in August 2009.

 

Former legal advisor to the United States Food and Drug Administration (FDA’s) Bureau of Medical Devices and Bureau of Foods, later executive assistant to the Commissioner of the FDA.

Later a partner at the law firm of King & Spaulding where he supervised a nine-lawyer group whose client included Monsanto Agricultural Company.

 

Still later Deputy Commissioner for Policy at the United States Food and Drug Administration. And later with the law firm of King & Spaulding, now head of the Washington, D.C. office of Monsanto Corporation.

 

Lidia Watrud.

Former microbial biotechnology researcher at Monsanto Corporation in St. Louis, Missouri, now with the United States Environmental Protection Agency Environmental Effects Laboratory, Western Ecology Division.

 

Jack Watson.

Former chief of staff to the President of the United States, Jimmy Carter, now a staff lawyer with Monsanto Corporation in Washington, D.C. 

 

Clayton K. Yeutter.

Former Secretary of the U.S. Department of Agriculture, former U.S. Trade Representative (who led the U.S. team in negotiating the U.S. Canada Free Trade Agreement and helped launch the Uruguay Round of the GATT negotiations), now a member of the board of directors of Mycogen Corporation, whose majority owner is Dow Agro Sciences, a wholly owned subsidiary of the Dow Chemical Company.

Larry Zeph.

Former biologist in the Office of Prevention, Pesticides, and Toxic Substances, U.S. Environmental Protection Agency, now Regulatory Science Manager at Pioneer Hi-Bred International.

 

Margaret Miller

Michael Taylor

Suzanne Sechen

(An FDA ‘primary reviewer for all rbST and other dairy drug production applications”) were the subjects of a U.S. General Accounting Office (GAO) investigation in 1994 for their role in the U.S. Food and Drug Administration’s approval of Posilac, Monsanto Corporation’s formulation of recombinant bovine growth hormone (rbST or rBGH). The GAO Office found “no conflicting financial interests with respect to the drug’s approval” and only “one minor deviation from now superseded FDA regulation”. (Quotations are from the 1994 GAO report).

 

 

Exert from the Supreme Court case, No. 06-1249

Wyeth a pharmaceutical company, Petitioner.

vs.

Diana Levine, Respondent.

Sources

American Bar Association

Common Sense Of Contemporary American Economics And Politics by Kurt Lewis Allen

Future of Food DVD Documentary by Deborah Koons Garcia Lily Films

Images by Pixaby